Development and validation of a nomogram to predicting the efficacy of PD-1/PD-L1 inhibitors in patients with...

Area of Science:

• Oncology
• Immunotherapy
• Biomarker Discovery

Background:

• Nasopharyngeal carcinoma (NPC) treatment increasingly utilizes PD-1/PD-L1 inhibitors.
• Predicting patient response to immunotherapy is crucial for personalized treatment strategies.

Purpose of the Study:

• To develop and validate a predictive nomogram for evaluating immunotherapy efficacy in NPC patients.
• To identify reliable hematological markers for predicting treatment outcomes.

Main Methods:

• A cohort of 160 NPC patients was analyzed.
• Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression screened hematological markers.
• A nomogram was constructed and validated internally and externally using various statistical metrics.

Main Results:

• Systemic Immune-Inflammation Index (SII) and ALT to AST Ratio (LSR) were identified as key predictive markers.
• The nomogram demonstrated good predictive performance with a C-index of 0.745 (training) and 0.760 (validation).
• The model showed superior predictive ability compared to TNM staging, with AUC values of 0.745 (training) and 0.878 (validation).

Conclusions:

• The developed nomogram accurately predicts the efficacy of PD-1/PD-L1 inhibitors in NPC patients.
• This tool can assist clinicians in selecting appropriate patients for immunotherapy.
• The nomogram provides a valuable, non-invasive method for treatment response evaluation.